These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 32751931)

  • 1. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
    Kandil S; Prencipe F; Jones S; Hiscox S; Westwell AD
    Chem Biol Drug Des; 2018 Jan; 91(1):314-321. PubMed ID: 28816016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
    Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
    Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
    Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative and antimetastatic properties of 3-benzyloxy-16-hydroxymethylene-estradiol analogs against breast cancer cell lines.
    Sinka I; Kiss A; Mernyák E; Wölfling J; Schneider G; Ocsovszki I; Kuo CY; Wang HC; Zupkó I
    Eur J Pharm Sci; 2018 Oct; 123():362-370. PubMed ID: 30010030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
    Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
    J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H; Lin X; Zhang Y; Tan F; Chi B; Peng Z; Dong W; An D
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127459. PubMed ID: 32784087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y; Li R; Ning X; Lin Z; Zhao X; Zhou J; Liu J; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 177():32-46. PubMed ID: 31129452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
    Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
    Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
    Dao P; Lietha D; Etheve-Quelquejeu M; Garbay C; Chen H
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1727-1730. PubMed ID: 28284808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and characterization of novel FGFR1 inhibitors in triple-negative breast cancer via hybrid virtual screening and molecular dynamics simulations.
    Wang Y; Shen Z; Chen R; Chi X; Li W; Xu D; Lu Y; Ding J; Dong X; Zheng X
    Bioorg Chem; 2024 Sep; 150():107553. PubMed ID: 38901279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronidazole aryloxy, carboxy and azole derivatives: Synthesis, anti-tumor activity, QSAR, molecular docking and dynamics studies.
    Faghih-Mirzaei E; Sabouri S; Zeidabadinejad L; AbdolahRamazani S; Abaszadeh M; Khodadadi A; Shamsadinipour M; Jafari M; Pirhadi S
    Bioorg Med Chem; 2019 Jan; 27(2):305-314. PubMed ID: 30554970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and docking studies of novel 4-aminophenol-1,2,4-oxadiazole hybrids as apoptosis inducers against triple negative breast cancer cells targeting MAP kinase.
    Dhanalakshmi B; Anil Kumar BM; Srinivasa Murthy V; Srinivasa SM; Vivek HK; Sennappan M; Rangappa S
    J Biomol Struct Dyn; 2024 Jul; 42(11):5841-5857. PubMed ID: 37529915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer.
    Yang F; Xu K; Zhang S; Zhang J; Qiu Y; Luo J; Tan G; Zou Z; Wang W; Kang F
    Bioorg Med Chem; 2022 Jul; 66():116809. PubMed ID: 35569251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
    Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
    Wang K; Zou P; Zhu X; Zhang T
    Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.